Drugs / TAK-448
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01132404 | Nov 2010 → Sep 2011 | prostate cancer | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02381288 | Sep 2015 → Apr 2016 | hypogonadism, male | Takeda | Terminated | No outcome recorded |
| Phase 2 | NCT02369796 | Feb → Oct 2015 | hypogonadotropic hypogonadism | Takeda | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-448 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02369796 ↗ |
| Modality | Small molecule | — CHEMBL3924151 ↗ |
| Route | Subcutaneous | “via subcutaneous abdominal injection” NCT01132404 ↗ |